Previous 10 | Next 10 |
Acasti Pharma (NASDAQ: ACST ) resume with Buy rating and $8 (292% upside) price target at B. Riley FBR. Shares up 5% premarket. More news on: Acasti Pharma Inc., Champions Oncology, Inc., DexCom, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Yesterday, an FDA advisory committee panel voted 16 to 0 to approve an expanded label for Amarin's ( AMRN ) Vascepa that will make it a multi-billion-dollar blockbuster drug that could potentially outshine the performance of Humira and Lipitor. As I watched the committee members debating on ...
Plus Therapeutics (NASDAQ: PSTV ) +30% after Q3 results . More news on: Plus Therapeutics, Inc., Farfetch Limited, RadNet, Inc., Stocks on the move, Read more ...
Cardiovascular disease events like heart attacks, stroke and death affect millions of patients in the United States and are estimated to cost $500 billion annually Millions of high-risk patients with cardiovascular disease could benefit from this cost-effective therapy if expanded l...
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that NASDAQ has halted trading of the company's shares. The U.S. Food and Drug Administrat...
The FDA briefing documents for the November 14 AdCom meeting are a strong positive for Amarin ( AMRN ). The conclusion was that "the benefit-risk assessment favors the use of Vascepa for CVD risk reduction". Mineral oil was seen as only having a 3% impact on the CVD risk in the worst-case sc...
Amarin ( AMRN ) has a crucial FDA advisory committee meeting tomorrow, November 14th. The webcast can be accessed here . Briefing documents have been released. Here we will study them. In general, there are two kinds of briefings - one from the FDA, which is more important for understanding...
Yesterday, Amarin 's (NASDAQ: AMRN) shares jumped by a whopping 20.9% during normal trading hours. The spark behind this eye-catching move northward was the release of the U.S. Food and Drug Administration's (FDA) briefing materials for the company's upcoming advisory-committee meeting set ...
November 13, 2019 Palm Beach, FL –November 13, 2019 – For decades researchers have been trying to find newer and more effective ways to fight cancer cells. Today much research is focused on attacking the cancerous cells growth. The reasoning is that denying these cells e...
Major benchmarks got out to a strong start on Tuesday, but initial enthusiasm about a potential breakthrough in the U.S.-China trade negotiations gave way to a more realistic assessment of where things stand between the two nations. Investors are still trying to balance worries about economic ch...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...